- Oops!Something went wrong.Please try again later.
Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in advanced solid malignancies.
Paclitaxel is one of the most commonly used chemotherapies.
Data were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021.
The dose-escalation phase of the study enrolled 21 patients. Activity data were presented on 17 evaluable patients.
Four patients had a partial response, ten patients had stable disease, and three had progressive disease.
There were ten non-small cell lung cancer (NSCLC) patients enrolled, of which eight were evaluable for response.
Four patients achieved a partial response, and four patients achieved stable disease.
All the patients had discontinued previous checkpoint inhibitor therapy due to progressive disease.
The maximum tolerated dose of the combination was not reached.
Price Action: ATNX shares are up 1.77% at $3.45 during the premarket session on the last check Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.